Heartland Advisors’s Anavex Life Sciences AVXL Stock Holding History

Heartland Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-177,350	Closed	-$1.58M	–	257
2025 Q3	$1.58M	Hold	177,350	–	–	0.08%	192
2025 Q2	$1.64M	Buy	177,350 +22,700	+15%	+$194K	0.09%	186
2025 Q1	$1.33M	Sell	154,650 -1,200	-0.8%	-$11.3K	0.08%	186
2024 Q4	$1.67M	Buy	+155,850	New	+$1.2M	0.09%	179

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Heartland Advisors's AVXL Position: Q4 2025 in Review

Heartland Advisors sold out of Anavex Life Sciences (AVXL) in Q4 2025, closing a stake of 177,350 shares — an estimated $1.58M sold.

Heartland Advisors first reported a position in AVXL in Q4 2024 and held it in 4 quarters. The position peaked at $1.67M in Q4 2024. 184 funds tracked by Wall St. Rank hold AVXL as of Q4 2025.

Heartland Advisors reported no remaining Anavex Life Sciences position as of Q4 2025 after selling out during the quarter.
Heartland Advisors sold 177,350 Anavex Life Sciences shares in Q4 2025, an estimated $1.58M.
Heartland Advisors first reported a position in Anavex Life Sciences in Q4 2024 and held it in 4 quarters.
Heartland Advisors's Anavex Life Sciences position peaked at $1.67M in Q4 2024.
184 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2025.

Based on Heartland Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.